Rx Product News (February 2015)

Pharmacy Times, February 2015 Autoimmune Disorders, Volume 81, Issue 2

Read about the new Rx Products featured in February.

Biocryst Pharmaceuticals, Inc

Indication: The FDA has approved Rapivab (peramivir), an influenza virus neuraminidase inhibitor, for the treatment of acute uncomplicated influenza in adults who have been symptomatic for no more than 2 days. The recommended dosage is a single dose of 600 mg administered by intravenous infusion for a minimum of 15 minutes within 2 days of the onset of influenza symptoms. The dosage should be reduced to 200 mg for patients with a baseline creatinine clearance of 30 to 49 mL/min, and reduced to 100 mg for patients with a baseline creatinine clearance of 10 to 29 mL/min.

Dosage Form: Injection: 200 mg in 20 mL (10 mg/mL) in a single-use vial

For More Information: www.rapivab.com

DylojectMarketed by: Hospira, Inc

Indication: The FDA has approved Dyloject (diclofenac sodium), a nonsteroidal anti-inflammatory drug, for the management of mild to moderate pain or the management of moderate to severe pain alone or in combination with opioid analgesics in adults. The recommended dosage is 37.5 mg administered by intravenous bolus injection over 15 seconds. The treatment may be repeated every 6 hours, not to exceed 150 mg/ day. Patients should be well hydrated before Dyloject is administered.

Dosage Form: Injection: 37.5 mg/mL in a single-dose vial

For More Information: www.dyloject.com

JakafiMarketed by: Incyte Corporation

Indication: The FDA has approved Jakafi (ruxolitinib), a kinase inhibitor, for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. The recommended starting dosage for patients with polycythemia vera is 10 mg orally twice daily.

Dosage Form: Tablets: 5, 10, 15, 20, and 25 mg

For More Information: www.jakafi.com

XgevaMarketed by: Amgen, Inc

Indication: The FDA has approved Xgeva (denosumab), a RANK ligand inhibitor, for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy. The recommended dosage for patients with HCM is 120 mg subcutaneously in the upper arm, upper thigh, or abdomen every 4 weeks, with additional 120-mg doses on days 8 and 15 during the first month of therapy.

Dosage Form: Injection: 120 mg/1.7 mL (70 mg/mL) solution in a singleuse vial

For More Information: www.xgeva.com